Dr. Postow on BRAF and MEK Inhibitor Combination Studies in Melanoma

Michael A. Postow, MD
Published: Friday, Oct 20, 2017



Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

There are 2 BRAF and MEK studies for patients with stage III resected melanoma. The BRIM8 study investigated vemurafenib (Zelboraf) versus placebo, states Postow. The other study is the COMBI-AD study, which investigated dabrafenib (Tafinlar) plus trametinib (Mekinist) versus placebo for patients with stage III resected melanoma.

According to Postow, both studies had interesting biologic effects demonstrating efficacy.

<<< View more from the World Congress of Melanoma


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.

There are 2 BRAF and MEK studies for patients with stage III resected melanoma. The BRIM8 study investigated vemurafenib (Zelboraf) versus placebo, states Postow. The other study is the COMBI-AD study, which investigated dabrafenib (Tafinlar) plus trametinib (Mekinist) versus placebo for patients with stage III resected melanoma.

According to Postow, both studies had interesting biologic effects demonstrating efficacy.

<<< View more from the World Congress of Melanoma



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x